| abstract |
An object of the present invention is to provide a nucleic acid drug having a higher effect and a longer duration of suppressing the expression of α-synuclein. The oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains at least one 2′-O, 4′-C-ethylene nucleoside, is capable of binding to the α-synuclein gene, and the α-synuclein A nucleotide that has an activity of suppressing the expression of a gene and is complementary to the α-synuclein gene, and that is complementary to a specific nucleotide is at the 5'end, and is complementary to at least a part of SEQ ID NO: 1. , 13-15 nucleotides in length. |